** Shares of AI-based drug developer Absci ABSI.O down 14.8% at $2.99 premarket
** ABSI late Thursday sold 16.67 million shares at $3 apiece for gross proceeds of $50 million
** Stock offering priced at 14.5% discount to last close
** Proceeds will be used to advance its drug creation platform and other purposes
** Morgan Stanley, J.P.Morgan, Jefferies and TD Cowen were joint book-running managers for the offering
** ABSI had 127.54 million outstanding shares, as of March 31, according to offering prospectus
** All 9 brokerages covering the stock rate "buy" or higher; median PT $9 - data compiled by LSEG
** As of last close, ABSI shares up 34% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。